Fresenius Medical Care (NYSE:FMS) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report issued to clients and investors on Tuesday. The firm set a “strong-buy” rating on the stock.

Separately, Truist Financial increased their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $23.00.

Fresenius Medical Care Stock Performance

FMS opened at $20.59 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09. The company has a market capitalization of $12.08 billion, a price-to-earnings ratio of 23.13, a P/E/G ratio of 1.08 and a beta of 0.91. The business’s 50-day moving average price is $19.77 and its two-hundred day moving average price is $20.01. Fresenius Medical Care has a 1 year low of $16.37 and a 1 year high of $22.76.

Fresenius Medical Care (NYSE:FMS) last released its earnings results on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, meeting the consensus estimate of $0.38. The firm had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.28 billion. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. Equities analysts expect that Fresenius Medical Care will post 1.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC raised its stake in shares of Fresenius Medical Care by 21.8% during the 1st quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock worth $82,000 after purchasing an additional 758 shares in the last quarter. ORG Partners LLC acquired a new stake in Fresenius Medical Care in the first quarter valued at $110,000. SageView Advisory Group LLC bought a new position in shares of Fresenius Medical Care in the 1st quarter valued at about $127,000. Signaturefd LLC increased its stake in shares of Fresenius Medical Care by 8.4% during the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock worth $166,000 after purchasing an additional 672 shares during the last quarter. Finally, Kimelman & Baird LLC bought a new stake in shares of Fresenius Medical Care in the 2nd quarter valued at about $186,000. 8.25% of the stock is currently owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.